← FDA DRUG APPROVALS

FDA ANDA · ANDA211660

DEFERASIROX

Sponsor: JUBILANT GENERICS

APPLICATION
ANDA211660
TYPE
ANDA
ORIGINAL APPROVAL
2025-04-11
LATEST ACTION
2025-04-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

DEFERASIROXPrescription
DEFERASIROX 180MG · TABLET · ORAL
DEFERASIROXPrescription
DEFERASIROX 360MG · TABLET · ORAL
DEFERASIROXPrescription
DEFERASIROX 90MG · TABLET · ORAL

Approval history

2025-04-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →